Filip Conic
Filip Conic is a Partner at Roland Berger with a focus on Life Sciences. His consulting clients primarily include pharmaceuticals and medical technology producers, companies active in the pharmaceutical wholesale and retail sector alongside other healthcare providers, as well as a range of related industries.
He has specialized in developing corporate and medical strategies, managed large-scale organizational transformation projects and executed commercial excellence programs. The cornerstones of his expertise are route to market, omnichannel strategies, pricing, commercial terms and conditions alongside market access and reimbursement strategies. In addition, he has extensively supported private equity and corporate investors from various geographies along the entire investment cycle (evaluation of investment opportunities, value creation programs following the successful investment and exit support).
Filip has lived, studied and worked in Austria, Germany, Liechtenstein, Switzerland, Serbia and the US, while his project experience spans a range of countries across Europe, Russia and North America. He has an interdisciplinary background and holds a master's degree in Business Administration from the University of Cologne, Germany.
Global Pharma Study 2024 – a new age of performance programs
Study, October 22, 2024
The era of free drug-pricing in the US has come to an end
Article, September 17, 2024
US pharmaceutical pricing at a crossroads
Article, February 5, 2024
Cell and gene therapies: Strategies for commercial success
Article, November 14, 2023
Will environmental sustainability hold sway over the pharmaceuticals industry?
Article, November 29, 2022
Future of health 3 - How the phygital model is going to transform healthcare
Study, September 24, 2021
Available in DE
Austria's hospitals suffer from the consequences of the pandemic
Study, December 17, 2020